
Opinion|Videos|August 6, 2024
Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
Author(s)Kaleb H. Yohay, MD
A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.
Advertisement
Episodes in this series

- Mirdametinib is currently being investigated as a treatment option for adolescents and adults who have transitioned out of adolescent care who are living with NF1-PN. Can you comment on the recent phase II data?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup
2
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
3
CN045 Promotes Oligodendrocyte Maturation, Modest Remyelination in Preclinical MS Study
4
Ractigen Completes Phase 2 Enrollment for RAG-17 in SOD1-ALS
5














